The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed
after the initial 3 month avoidance period
Secondary Objectives:
- Identify the basic immune mechanisms which can explain the differences in the effects of
OIT in desensitized vs. tolerant individuals.
- Determine whether immune monitoring measurements reflecting underlying mechanisms during
OIT can be used to predict responses to OIT in individual subjects and, ultimately, to
improve the safety and efficacy outcomes in peanut OIT protocols.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)